• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 19 of 100
CommentaryHoward Dean: ‘At last, Congress proposes drug pricing reform that works’
By Howard DeanSeptember 19, 2023
a box of wegovy medication
RetailWegovy maker Novo Nordisk leapfrogs LVMH to become Europe’s most valuable company after it takes its ‘miracle’ weight loss drug to the U.K.
By Prarthana PrakashSeptember 5, 2023
CommentarySmoke and mirrors: I’ve been debating Vivek Ramaswamy for 2 years. Here’s how I got past his diversionary tactics
By Jeffrey SonnenfeldAugust 31, 2023
CommentaryU.S. health care has been in crisis since Nixon–but two economists may have found a way to radically disrupt it
By John G. SingerAugust 10, 2023
HealthPopular weight-loss injectable Wegovy cuts risk of heart attack and stroke by 20%, company says
By Erin PraterAugust 8, 2023
Diabetes drug Ozempic
MagazineNovo Nordisk developed Ozempic and started a weight-loss revolution. Its next moonshot is eliminating obesity altogether
By Vivienne WaltJuly 31, 2023
HealthOzempic manufacturer Novo Nordisk spent $11 million last year ‘wining and dining’ doctors. Experts slam the move as a breach of doctor-patient trust
By Erin PraterJuly 21, 2023
NewslettersDigitalization could be the answer to better health care for patients. But first, they need to trust it
By Eamon BarrettJuly 21, 2023
HealthBiden administration pushes Walgreens, CVS and Walmart to tout drug cost benefits of Inflation Reduction Act as drugmakers sue government
By Riley Griffin and BloombergJuly 19, 2023
NYSE trader
FinanceThe A.I. mania is so red hot that a small $50 million investment from Nvidia sent an obscure biotech firm’s shares up a record 78%
By Angel Adegbesan and BloombergJuly 12, 2023
woman at mirror
HealthOzempic isn’t alone. A whole class of ‘revolutionary’ weight-loss drugs is on the market—but only for the wealthy
By Rachel ShinJuly 9, 2023
SuccessEli Lilly’s CEO pinpoints the 3-prong problem big execs face with remote work
By Jane ThierJune 24, 2023
Ozempic is pictured in a pharmacy on April 13, 2023 in Niesky, Germany.
FeaturesThe maker of Ozempic and Wegovy is researching groundbreaking new drugs to stop people from becoming obese in the first place
By Vivienne WaltJune 21, 2023
HealthThe ADHD drug shortage is spreading as supplies of a popular alternative to Adderall run worryingly low
By Ike Swetlitz and BloombergJune 20, 2023
Paul Hudson
SuccessGen Z needs brand-new skills to climb to the C-suite: ‘What got me here will not get them there,’ says health care CEO
By Jane ThierJune 2, 2023
1...
  • 17
  • 18
  • 19
  • 20
  • 21
...100
Most Popular
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House postAn image of a popular article
By Eleanor PringleFebruary 4, 2026
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’An image of a popular article
By Emma BurleighFebruary 2, 2026
Investing
Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the boardAn image of a popular article
By Jim EdwardsFebruary 4, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.